Adar Poonawalla (File Image: Twitter)
The Serum Institute of India (SII) is “hopeful” of getting emergency use authorisation (EUA) for its vaccine by December-end, as per CEO Adar Poonawalla.
“We might get emergency license by this month-end, but licence for wider use might come at a later date. But, we are confident that if the regulators give a nod, India's vaccination drive can start by January 2021,” Poonawalla said at the Economic Times Global Business Summit.
Follow our LIVE Updates on the coronavirus pandemic here
He further said that the Health Ministry is planning to vaccinate 20-30 percent of India’s population to reach a critical mass, which once happens “will can hopefully see confidence and sentiments coming back.” The government wants 300-400 million doses by July 2021, he added.
“By September-October 2021 hopefully there will be enough vaccines for everyone and normal life can return,” he said.
Check here for the latest updates on all COVID-19 vaccines
Poonawalla said SII “is preparing” to manufacture enough vaccines for the government and private markets, and has signed an agreement with Novavax to manufacture COVID-19 vaccines. It aims to finish Phase 3 clinical trial for Novavax by Q1FY21.
However, Poonawalla’s timelines could be a bit optimistic, reports find, as state governments are planning to provide only 100 shots per day at each vaccination site.
So far, India has recorded 9,826,775 confirmed COVID- 19 cases, including 142,628 deaths. A total of 9,324,328 patients have recovered, as per the latest data from the Union Health Ministry. However, there are 359,819 active cases in the country, which comprise 3.66 percent of the total caseload. India's recovery rate continues to rise and now stands at 94.74 percent. The country conducted 1,065,176 tests during the previous 24-hour cycle.
Globally, more than 7.10 crore people have been infected by the novel coronavirus and 15.94 lakh have died so far.Follow our full COVID-19 coverage here